Ann: Approval to start Efti & Bavencio trial in urothelial cancer, page-5

The recent quarterly report demonstrated increased expenditure (as expected with increased activity), problem is the revenue or lack thereof isn't keeping up.

I suggest that the decisions have already been made about where to from here and we will know we'll before end CY23. I'm not confident short term, agree dilution is on our future.

Long term, perhaps another story, though ny then, with dilution the 5 x return may just land me back at the start.

Personally I can't wait for the next version of long term holding, 10years enough for me.

Here's hoping for a quick full TO event.